Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
325 studies found for:    Open Studies | "Triplets"
Hide Display Options

Display Options

Study Details
Participant Details
Identifiers
Dates
Rank Status Study
1 Available Comparison Study of Adjuvant Chemotherapy for Chinese Triple Negative Breast Cancer
Condition: Triple Negative Breast Cancer
Intervention: Drug: Paclitaxel Cisplatin
2 Recruiting TC (Docetaxel/Carboplatin) Versus EC-T (Epirubicin/Cyclophosphamide Followed by Docetaxe) as Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer
Condition: Triple-Negative Breast Cancer
Intervention: Drug: TC (docetaxel/carboplatin) versus EC followed by T (epirubicin/cyclophosphamide followed by docetaxe)
3 Recruiting Cisplatin vs Paclitaxel for Triple Neg
Condition: Triple Negative Breast Cancer
Interventions: Drug: Cisplatin;   Drug: Paclitaxel
4 Recruiting Patient-derived Xenograft (PDX) Modeling of Treatment Response for Triple Negative Breast Cancer
Condition: Triple Negative Breast Cancer
Intervention: Other: Chemotherapy
5 Recruiting Effects of MK-3475 (Pembrolizumab) on the Breast Tumor Microenvironment in Triple Negative Breast Cancer
Condition: Triple Negative Breast Cancer
Interventions: Drug: Merck 3475 Pembrolizumab;   Radiation: Intraoperative radiation therapy (IORT)
6 Not yet recruiting Phase II Study of IMMU-132 Alone or in Combination With Carboplatin in Patients With Triple-Negative Breast Cancer
Condition: Triple-negative Breast Cancer
Interventions: Drug: IMMU-132 infusion is administered to participants in one arm for the study;   Drug: IMMU-132 plus Carboplatin infusion
7 Recruiting Comparison of Biological Features Between pN0 Triple Negative Breast Tumours With Size < or = 10 mm (pT1a/b) Versus pT1c T2 < or = 30 mm
Condition: Triple Negative Breast Cancers Without Lymph-node Involvement and < or = 30 mm
Intervention: Procedure: Blood samples of 10 mL
8 Recruiting Ixazomib (MLN9708) in Combination With Carboplatin in Pretreated Women With Advanced Triple Negative Breast Cancer
Condition: Triple-Negative Breast Cancer
Interventions: Drug: Ixazomib;   Drug: Carboplatin
9 Recruiting Safety and Efficacy Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy as Neoadjuvant Treatment for Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-173/KEYNOTE 173)
Condition: Triple Negative Breast Neoplasms
Interventions: Biological: Pembrolizumab;   Drug: Nab-paclitaxel;   Drug: Anthracycline (doxorubicin);   Drug: Cyclophosphamide;   Drug: Carboplatin;   Drug: Paclitaxel
10 Recruiting Neoadjuvant Treatment of Triple Negative Breast Cancer Patients With Docetaxel and Carboplatin to Assess Anti-tumor Activity
Condition: Triple Negative Breast Neoplasms
Interventions: Drug: Docetaxel;   Drug: Carboplatin
11 Recruiting Study Of Single-dose Cyclophosphamide +Pembrolizumab In Patients With Metastatic Triple Negative Breast Cancer
Condition: Triple Negative Breast Cancer
Interventions: Drug: Pembrolizumab;   Drug: Cyclophosphamide
12 Recruiting Neoadjuvant Study of Two Platinum Regimens in Triple Negative Breast Cancer
Condition: Triple-negative Breast Cancer
Interventions: Drug: Paclitaxel;   Drug: Carboplatin;   Drug: Doxorubicin;   Drug: Cyclophosphamide;   Drug: Docetaxel
13 Recruiting Pilot Study of Veliparib (ABT-888) and Lapatinib (Tykerb) in Patients With Metastatic, Triple Negative Breast Cancer
Condition: Metastatic Triple Negative Breast Cancer
Intervention: Drug: Combination of Veliparib + Lapatinib
14 Recruiting Study Evaluating Efficacy and Safety of SAR566658 Treatment in Patients With CA6 Positive Metastatic Triple Negative Breast Cancer
Condition: Triple Negative Breast Cancer
Intervention: Drug: SAR566658 (ACT14884)
15 Recruiting Efficacy and Safety of GTx-024 in Patients With Androgen Receptor-Positive Triple Negative Breast Cancer (AR+ TNBC)
Condition: Triple Negative Breast Cancer
Intervention: Drug: GTx-024
16 Recruiting Adjuvant Treatment for High-risk Triple Negative Breast Cancer Patients With the Anti-PD-l1 Antibody Avelumab: A Phase III Randomized Trial
Condition: Triple Negative Breast Neoplasms
Intervention: Drug: MSB0010718C
17 Not yet recruiting Neoadjuvant Chemotherapy Docetaxel With or Without SELUMETINIB in Patients With Triple Negative Breast Cancer
Condition: Triple Negative Breast Cancer
Interventions: Drug: Drug: Selumetinib;   Drug: Doxorubicin;   Drug: Cyclophosphamide;   Drug: Docetaxel
18 Recruiting A Study of Atezolizumab in Combination With Nab-Paclitaxel Compared With Placebo With Nab-Paclitaxel for Participants With Previously Untreated Metastatic Triple-Negative Breast Cancer (IMpassion130)
Condition: Triple Negative Breast Cancer
Interventions: Drug: Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody;   Drug: Nab-Paclitaxel;   Drug: Placebo
19 Not yet recruiting A Study of Atezolizumab and Paclitaxel Versus Placebo and Paclitaxel in Participants With Previously Untreated Locally Advanced or Metastatic Triple Negative Breast Cancer (TNBC)
Condition: Triple-Negative Breast Cancer
Interventions: Drug: Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody;   Drug: Atezolizumab Placebo;   Drug: Paclitaxel
20 Recruiting A Trial Evaluating the Efficacy and Safety of EndoTAG®-1 in Combination With Paclitaxel and Gemcitabine Compared With Paclitaxel and Gemcitabine as First-line Therapy in Patients With Visceral Metastatic Triple-negative Breast Cancer
Condition: Triple-Negative Breast Cancer
Interventions: Drug: EndoTAG-1;   Drug: Paclitaxel;   Drug: Gemcitabine Hydrochloride

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.